Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Arrowhead Pharmaceuticals, Inc.

ARWR

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Arrowhead Pharmaceuticals, Inc.. A complete text table follows the diagram.

Arrowhead Advances RNA Medicines Through Partnerships

Revenue remains partnership-driven and volatile as Arrowhead advances RNA medicines.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0000879407-26-000047
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The filing reports $73.737M revenue; no unsupported collaboration split is added.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Arrowhead Pharmaceuticals revenue	1	$73.7M	$73.7M reported quarterly revenue
RNA medicines partnership revenue	2	$73.7M	Reported quarterly revenue

Financial flows · Millions of USD
From	To	Value
Arrowhead Pharmaceuticals revenue	RNA medicines partnership revenue	$73.7M